March 31, 2020 – COVID-19
On March 17, the US Secretary of Health and Human Services issued a declaration to provide liability immunity for activities related to medical countermeasures against COVID-19. As a result, potential research subjects...
COVID-19 Updates for DF/HCC
The information on this page applies to all research conducted under the Dana-Farber/Harvard Cancer Center.
For additional information please see:
Please also consult officials at your home institution for specific information about restrictions, guidance, and changes at your institution.
- BIDMC: Please contact the CCTO for specific information.
- DFCI: Research staff employed by DFCI must follow information on the DFCI Online COVID-19 page and specific information for DFCI researchers.
- MGH: Please contact the CCPO for more information.
- Other DF/HCC member institutions should contact their institutional leadership for information specific to your location.
Important Documents
Recent Announcements
-
-
March 23, 2020 – COVID-19
Please read carefully for information on approved policy exceptions, additional clarifications, and a note-to-file document
-
March 18, 2020 – COVID-19
Clarifications regarding DF/HCC consent requirements for human subject oncology research in response to shared Partner's communications
-
March 14, 2020 – COVID-19
To all staff participating in human subject research at DF/HCC: Below is some additional information to clarify what changes require prospective review and approval by the DFCI IRB in light of the steps we...